Major EU Q-AID Consortium Launches to Integrate Quantum-Enhanced MRI with AI for Advanced Diagnostics

ULM, Germany—We officially kicked-off the Q-AID project with the first in-person meeting between the research partners from IBEC, University of Antwerp and our industry AI teams from Gemelli Biotech, Aarhus University, DPU and CEA.

Q-AID’s mission is to integrate quantum-enhanced hyperpolarized MRI imaging with advanced AI, opening new possibilities for diagnosis and treatment of cancer, Alzheimer’s disease, and multiple sclerosis.

As part of the European Commission’s Quantum Europe Strategy, Q-AID helps to position Europe as a global leader in quantum innovation.

Learn more about Q-AID ↗

ULM, Germany - We joined the annual General Assembly of QuE-MRT, for a day focused on discussions and updates for advancing metabolic imaging.

This German flagship project is focused on building an end-to-end clinical platform for quantum-enhanced hyperpolarized metabolic MRI, including R&D work on the polarizer and MRI acquisition methods, preclinical research on cancer models, regulatory effort towards clinical studies in Germany and ultimately running clinical studies on 3 different cancer patient populations.

Once again, we were impressed by the progress happening on so many fronts:
- Standardized MRI acquisition protocols enabling broader adoption
- New, promising metabolic probes (like Z-OMPD and α-KIC)
- Key advances in the regulatory process toward the first clinical HP-MRI studies in Germany

Learn more about QuE-MRT ↗